Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 361 across all filing types
Latest filing 2025-09-11 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - NDA FOR KN026 (ANBENITAMAB INJECTION) ACCEPTED BY THE NMPA
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement on the Hong Kong Stock Exchange regarding acceptance of a New Drug Application (NDA) by China’s NMPA. It is not a financial report (annual, interim, earnings), nor does it relate to voting, board changes, dividends, share issues, M&A or legal proceedings. It is a general corporate/regulatory update. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2025-09-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025
Regulatory Filings Classification · 1% confidence The document is the FF301 “Monthly Return for Equity Issuer” under Hong Kong Exchange Listing Rules (Chapter 19B) showing detailed movements in authorized share capital, issued shares, share options, and other securities-related items. It is a routine regulatory filing and does not represent an Annual or Interim Report, earnings release, major shareholding notification, or specific share issue announcement. No one‐off event (e.g., M&A, dividend, director dealing) is described; rather, it’s a periodic submission of share capital movements. Therefore, it best fits the fallback category “Regulatory Filings” (RNS).
2025-09-03 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is an 'Interim Results Announcement' for Alphamab Oncology for the six months ended June 30, 2025. It contains detailed unaudited condensed consolidated financial statements (income statement, balance sheet), financial highlights, and a comprehensive Management Discussion and Analysis (MDA) section. As it provides substantive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-28 English
SUPPLEMENT ANNOUNCEMENT CONNECTED TRANSACTION - TECHNOLOGY DEVELOPMENT COLLABORATION WITH SUZHOU ALPHAMAB
Regulatory Filings Classification · 1% confidence The document is a supplemental regulatory announcement under HKEx listing rules updating payment terms for a previously disclosed connected party transaction. It is not a full report (e.g., no financial statements, no earnings data) nor a specific form like a 10-K or interim report, nor does it fit specialized categories such as M&A, dividends, or share issuances. It is therefore a general regulatory filing.
2025-08-18 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement titled “Positive Profit Alert” under Listing Rule 13.09(2)(a), providing key unaudited preliminary financial highlights for the six months ended June 30, 2025. It is not the full interim report but an initial market update on expected results (turnaround to profit). This matches the definition of an Earnings Release (initial announcement of periodic financial results, key highlights only). H1 2025
2025-08-13 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 1% confidence The document is an announcement by the company advising the date of the Board meeting for approving and publishing its interim results. It is not the interim report itself, nor does it include any financial data—it merely notifies the timing of the report’s publication. This matches the definition of a Report Publication Announcement (RPA).
2025-08-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.